Beyond psychedelics: set and setting in general psychiatric practice.
Zofia Kozak, Christopher W T Miller
International review of psychiatry (Abingdon, England) December 1, 2024 DOI: 10.1080/09540261.2024.2419662 via PubMed
Summary
AI-generated from the abstractPsychedelic compounds are gaining interest as potential treatments for psychiatric disorders. Although most psychiatrists will not directly administer these drugs, psychedelic research offers lessons that can improve conventional care. Central to this is the concept of 'set and setting'—the importance of mindset and environment for therapeutic outcomes. New findings suggest mechanistic overlap between psychedelics and serotonergic antidepressants: both modulate neurotrophins, enhance neuroplasticity, and reopen critical learning periods, shaped by environmental context. The paper argues that integrating insights from psychedelic research, particularly set and setting, can improve depression treatment in traditional psychiatric settings by optimizing non-pharmacological factors such as high-quality psychotherapy.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Topics | Neuroplasticity |
| Keywords | Psychotherapy Psychedelics Psychopharmacology Socioeconomic status |
| Citations | 7 |
| Key finding | Integrating insights from psychedelic research, especially the emphasis on set and setting, can improve depression treatment outcomes in traditional psychiatric settings by optimizing non-pharmacological factors like high-quality psychotherapy. |
Abstract
Psychedelic compounds continue gaining scientific and regulatory traction as potential new treatments for psychiatric disorders. While most psychiatrists will likely not work directly with these compounds, psychedelic research practices provide insights that may improve conventional psychiatric care. Through its emphasis on 'set and setting' (mindset and environment, respectively), psychedelic research highlights the importance of non-pharmacologic factors maximizing therapeutic outcomes. While psychedelics and serotonergic antidepressants are distinctly different in their subjective experience, new findings suggest mechanistic overlap between them. Both have been found to modulate neurotrophins, enhance neuroplasticity, and reopen critical periods of learning, molded by the environmental context in which they are administered. This paper will argue that by integrating insights from psychedelic research (particularly set and setting), depression treatment outcomes in traditional psychiatric settings can improve by optimizing non-pharmacological factors in treatment, including the provision of high-quality psychotherapy.